We’re exhibiting at World Clinical Biomarkers & CDx Summit!

Stop by our table for a deep dive into the future of oncology diagnostics!

September 3 – 6, 2024
Boston, MA

Together for a better healthcare journey

We are fully committed to providing unwavering support to our biopharma clients at every stage of the clinical trial process. Our aim is to deliver seamless end-to-end solutions without any compromises or unnecessary complexities. Our extensive portfolio includes a wide range of cfDNA and cfRNA NGS services, all backed by an exceptional project management team that sets us apart.

Join us for an insightful presentation by our experts on the use of cfHPV-DNA as a biomarker for HPV-associated OPSCC!

Expert presentation:

The Rise of cfHPV-DNA as a Biomarker for HPV-Associated OPSCC

Date: September 5, 2024; Day 2 TRACK B Clinical Biomarker Development

Time: 3:10 pm

Presented by: Anna Starus, Associate Director – Medical Affairs & Product Development, Sysmex Inostics


  • Assess patients’ trial eligibility, by determining patients’ HPV status and subtype with a simple blood draw.
  • Gain real-time insights into treatment response, by assessing dynamic changes in cfHPV-DNA quantitatively over the course of treatment.
  • Detect recurrent disease — including distant recurrence — early, with detection that precedes the current standard of care.
Our assays

Our vast portfolio of molecular assays yields informative data from ctDNA & cfRNA samples, aiding in host immune response evaluation & therapeutic monitoring biomarker identification.

cfHPV DNA Assay:


With the ability to reliably and consistently detect as low as 2 copies of cfHPV-DNA, HPV-SEQ makes a powerful tool for surveillance and monitoring during development of cancer therapies for HPV driven cancers.

Targeted Panel Assays:

Plasma-Safe-SeqS (PSS) Technology

Detecting low frequency somatic variants requires ultrasensitive liquid biopsy approaches. Our targeted approach balances the primary need for high sensitivity with the breadth of genomic coverage, providing confidence that somatic variants can be detected even at exceedingly low concentrations.

Broad Panel Assays:

Liquid Trace and Profile Plus Technology*

Our approach provides high sensitivity and specificity across a large set of genes. Our RNA capabilities go beyond fusion detection to include analyzing exon skipping, alternative splicing and gene expression.

Meet us at World CB & CDx
To meet with our team at the World CB & CDx, please complete this form and a team member will reach out to schedule a live meet and greet.

Would you like to learn more about:(Required)

Details about how we process your information are available in our Privacy Policy.